Avmapki Fakzynja Co-Pack: A Breakthrough in KRAS-Mutated Recurrent LGSOC
Overview and Indication
Avmapki Fakzynja Co-Pack, a co-packaged oral combination of avutometinib capsules and defactinib tablets, received accelerated approval from the U.S. FDA on May 8, 2025 for the treatment of adult patients with KRAS-mutated recurrent low-grade serous ovarian cancer (LGSOC) who have undergone at least one prior systemic therapy . This marks the first FDA-approved therapy specifically indicated for this rare and resilient cancer subtype
Path to Approval and Clinical Evidence
The FDA’s decision was based on promising results from the Phase 2 RAMP-201 trial (NCT04625270), which evaluated the efficacy of the combination in KRAS-mutated recurrent LGSOC patients
. In the final analysis, the confirmed confirmed overall response rate (ORR) was 44% (95% CI: 31–58), with the duration of response (DOR) ranging from 3.3 to 31.1 months
. Physicians leveraged a dosing regimen of avutometinib 3.2 mg orally twice weekly (Days 1 and 4) combined with defactinib 200 mg orally twice daily, administered for the first three weeks of each four-week cycle
Mechanism of Action
First-of-its-kind: No previously approved oral systemic options existed for PPGL—treatment relied on surgery or palliative options like Cabometyx, Cometriq, or sunitinib. Azedra, previously approved, was discontinued in 2023 due to limited use and production constraints ReutersFierce PharmaMerck.comWikipedia.
Enhanced Patient Care: Provides a non-surgical, oral option for managing advanced PPGL, potentially transforming the treatment landscape for eligible patients ReutersMerck.comFierce Pharma.
Mechanism of Action & Existing Approvals
Avutometinib acts as a RAF/MEK clamp, dual-inhibiting MEK signaling and preventing compensatory reactivation by RAF kinases—a distinct mechanism compared to traditional MEK inhibitors Verastem InvestorWikipedia.
Defactinib inhibits focal adhesion kinase (FAK), a critical mediator of resistance once the MAPK pathway is blocked Verastem InvestorDrugs.com.
Together, this combination delivers a more comprehensive blockade of the RAS/RAF/MEK/ERK (MAPK) signaling network, potentially overcoming resistance mechanisms
Regulatory Designations and Development Pathway
Regulatory support for the combination was strong:
Breakthrough Therapy Designation
Orphan Drug Designation
Priority Review, allowing for expedited FDA review, with the goal date initially set for June 30, 2025 Verastem Investor+1Business Wire.
The New Drug Application was accepted and completed by October 2024 Verastem Investor+1, enabling the accelerated pathway and early approval on May 8, 2025—well ahead of the PDUFA deadline Verastem InvestorU.S. Food and Drug Administration.
Safety Profile
Treatment-related adverse events were consistent with expectations from kinase inhibitors, including:
Common (≥ 25%) adverse reactions: nausea, fatigue, rash, diarrhea, musculoskeletal pain, edema, vomiting, abdominal pain, dermatitis acneiform, visual disturbances, stomatitis, pruritus, dyspnea, cough, and urinary tract infections Drugs.comU.S. Food and Drug AdministrationWikipedia.
Laboratory abnormalities: elevated creatine phosphokinase (CPK), elevated liver enzymes (AST, ALT), increased bilirubin, triglycerides, decreased hemoglobin, lymphocytes, platelets, neutrophils Drugs.com+1U.S. Food and Drug Administration.
Other safety considerations: ocular toxicities (e.g., visual impairment, vitreoretinal disorders), serious skin toxicity (photosensitivity, cutaneous reactions), hepatotoxicity, rhabdomyolysis—monitoring and dose adjustments are advised. Additionally, embryo-fetal toxicity necessitates contraception advice Verastem InvestorDrugs.com.
Unmet Need and Future Prospects
LGSOC is a rare ovarian subtype often resistant to standard chemotherapy and hormonal therapy, with survival measured in years rather than months Drugs.comVerastem Investor. Approximately 30% of LGSOC patients harbor KRAS mutations, placing them in a difficult-to-treat subgroup Drugs.com+1. Avmapki Fakzynja addresses this gap as the first targeted option for KRAS-positive recurrent LGSOC Verastem InvestorDrugs.com.
To convert this accelerated approval into full approval, a confirmatory trial is required. Verastem is conducting RAMP-301, a Phase 3 international trial comparing the combination against standard chemotherapy or hormonal therapy, potentially expanding its regulatory reach, including into KRAS wild-type LGSOC
Summary
Name: Avmapki Fakzynja Co-Pack (avutometinib + defactinib)
Approval: U.S. FDA accelerated approval, May 8, 2025
Indication: Adult patients with KRAS-mutated recurrent LGSOC after prior systemic therapy
Key Trial: Phase 2 RAMP-201, ORR 44%, DOR 3.3–31.1 months
Mechanism: Dual targeting of RAF/MEK and FAK to block MAPK-signaling and resistance
Safety: Manageable with known kinase inhibitor-related toxicities, plus specific monitoring needs
Looking Ahead: Phase 3 RAMP-301 confirmatory study underway
